OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 22,895 Cr.
- Current Price ₹ 2,000
- High / Low ₹ 2,250 / 1,163
- Stock P/E 280
- Book Value ₹ 514
- Dividend Yield 0.00 %
- ROCE 5.39 %
- ROE 2.60 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.89 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.52%
- Company has a low return on equity of -18.2% over last 3 years.
- Debtor days have increased from 86.2 to 105 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 21 | 128 | 39 | 172 | 1,445 | |
| 93 | 132 | 199 | 254 | 978 | |
| Operating Profit | -71 | -4 | -161 | -82 | 467 |
| OPM % | -334% | -3% | -415% | -48% | 32% |
| 1 | -128 | -526 | -143 | -94 | |
| Interest | 16 | 46 | 48 | 89 | 166 |
| Depreciation | 34 | 53 | 66 | 76 | 274 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 |
| Tax % | 0% | -0% | 0% | 0% | -73% |
| -121 | -231 | -800 | -391 | -18 | |
| EPS in Rs | -1.57 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 124% |
| TTM: | 740% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -18% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 |
| 386 | 1,182 | 864 | 571 | 942 | |
| 96 | 248 | 365 | 459 | 727 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,550 |
| 633 | 1,231 | 1,361 | 863 | 6,276 | |
| CWIP | 431 | 490 | 334 | 188 | 60 |
| Investments | 0 | 0 | 4 | 20 | 16 |
| 195 | 722 | 314 | 356 | 1,199 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,550 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -118 | -416 | -163 | -107 | -68 | |
| -207 | -692 | -68 | 511 | -201 | |
| 381 | 1,162 | 118 | -391 | 412 | |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 | 105 |
| Inventory Days | 87 | 615 | 258 | 133 | |
| Days Payable | 762 | 420 | 163 | 147 | |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 | 91 |
| Working Capital Days | -1,085 | 271 | -1,953 | -259 | 59 |
| ROCE % | -3% | -12% | -12% | 5% |
Documents
Announcements
-
General-Updates
15 Jul - Audited financial results for FY25 with profit turnaround; business merger effective April 2024; no changes in figures.
-
Announcement under Regulation 30 (LODR)-Change in Management
7 Jul - Appointment of Jeffrey Wong as Chief Business Officer effective July 7, 2025.
-
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
7 Jul - Pledge of 937,155 shares by Tenshi Pharmaceuticals on July 3, 2025 for business needs.
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 1 Jul
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jul - Newspaper publication - Notice of postal ballot and remote e-voting
Annual reports
No data available.
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.